Ph II Cilengitide Plus Bevacizumab for Recurrent Glioblastoma (GBM)
Status:
Withdrawn
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The goal of this clinical research study is to learn if cilengitide given in combination with
bevacizumab can help to control glioblastoma. The safety of this drug combination will also
be studied.
Cilengitide is designed to block the flow of blood to cancer cells, which may help to slow or
block the growth of cancer.
Bevacizumab is designed to block the growth of new blood vessels, which may help to slow or
block the growth of cancer.